NCT00002193View on ClinicalTrials.gov

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Amprenavir

Trial Locations (2)

33301

Children's Diagnostic Treatment Ctr, Fort Lauderdale

38105

Saint Jude Children's Hosp / Dept of Infect Diseases, Memphis

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002193 - Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors | Biotech Hunter | Biotech Hunter